Eosinophilic granulomatosis with polyangiitis (EGPA)
Conditions
Brief summary
The primary endpoint is the proportion of patients, who achieve remission at week 24 (defined as a Birmingham Vasculitis Score (BVAS) version 3 score of 0 and receipt of prednisolone of ≤ 4mg daily and no receipt of oral steroids above baseline dose in the 4 weeks prior to week 24).
Detailed description
(I) Time to first EGPA flare. (II) Total accrued weeks of remission defined as defined as a Birmingham Vasculitis Activity Score (BVAS) – version 3(11), score of 0 with mOCS dose of prednisolone/prednisolone ≤ 4mg/day and BVAS of 0.
Interventions
DRUGPLACEBO
Sponsors
Imperial College London Limited
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the proportion of patients, who achieve remission at week 24 (defined as a Birmingham Vasculitis Score (BVAS) version 3 score of 0 and receipt of prednisolone of ≤ 4mg daily and no receipt of oral steroids above baseline dose in the 4 weeks prior to week 24). | — |
Secondary
| Measure | Time frame |
|---|---|
| (I) Time to first EGPA flare. (II) Total accrued weeks of remission defined as defined as a Birmingham Vasculitis Activity Score (BVAS) – version 3(11), score of 0 with mOCS dose of prednisolone/prednisolone ≤ 4mg/day and BVAS of 0. | — |
Countries
Italy
Outcome results
None listed